What is your current preferred approach in the management of metasatic sarcomatoid NSCLC?
Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (IMmotion 151)?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center
Answered on
This is certainly a very relevant question not just as to the proper management of pulmonary sarcomatoid carcinoma but also other rare cancer subtypes in general where it is hard to know how to properly utilize information obtained on more common subtypes of the same malignancy. Many times we have t...
Join for free or sign in to see the full answer